ATHE - Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434 | Benzinga
MELBOURNE, Australia and SAN FRANCISCO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced promising new data related to ATH434 was presented at the Society for Neuroscience that took place November 11-15, 2023, in Washington, D.C.
The poster entitled, "Potent Antioxidant and Mitochondrial-protectant Effects of ATH434, a Novel Inhibitor of ?-Synuclein Aggregation with Moderate Iron-binding Affinity," presents new data indicating that ATH434 can preserve mitochondrial function after oxidative injury and exert direct anti-oxidant activity independent of its iron binding properties. These features were not observed with another iron binding agent approved for treating iron overload that was also investigated. The study was run under the direction of Dr. Daniel J. Kosman, Distinguished Professor of Biochemistry at the State University of New York at Buffalo.
David Stamler, M.D., Chief Executive Officer of Alterity, commented, "These exciting new data underscore the potential of ATH434 as a treatment for neurodegenerative diseases, including Parkinson's disease and related disorders. We have long known that ATH434 is able to reduce labile iron which, when elevated, can drive oxidative stress. The demonstrated mitochondrial protection may reveal additional mechanisms that augment its ability to slow disease progression. We are grateful for the valued contributions from our collaborators in Dr. Kosman's laboratory at SUNY-Buffalo."
The study, authored by Dr. Danielle Bailey, investigated the efficacy of ATH434 and comparator agents as mitochondrial protectants using a menadione-induced model of oxidative stress in a neuronal cell line. A suite of in-solution assays detailed the mechanisms underlying ATH434's direct antioxidant capacity. The poster presentation can be accessed ...